Martindale Pharma, the UK-based, international pharma company has signed a multi-year exclusive manufacturing agreement with Burton Hospitals NHS Foundation Trust
Under the terms of the agreement, Burton Hospitals NHS Foundation Trust will supply a number of Martindale Pharma’s key specialty generic products including Bismuth Iodoform Paraffin Paste (BIPP) and Lidocaine and Phenylephrine Topical Solution, both routine treatments in Ear Nose and Throat (ENT) surgery. Financial terms were not disclosed.
Michael Clark, chief marketing officer, commented: “This news follows two years of collaborative work with the Burton Hospital, one of our best performing contract manufacturing partners.
“We believe this new agreement demonstrates how pharmaceutical companies can support NHS manufacturing units and offer patients the best drugs currently available on the market.”
Martindale Pharma said it is recognised as a strategic partner to the NHS and for the past six years has worked with the UCL School of Pharmacy and London North West Healthcare NHS Trust’s Q3P Qualified Person (QP) Training Course providing academic and practical training to NHS Qualified Person trainees: as part of the course the pharmaceutical packaging module is hosted annually at Martindale Pharma’s Romford facility.
Clark added: “We are very pleased to be able to share our expertise and knowledge in the manufacturing industry with trainee QPs and NHS Manufacturing units.
“Our expertise, combined with our modern, upgraded UK manufacturing facility not only allows us to manufacture high quality medicines efficiently, but supply these to a wide range of countries and health care systems, notably the UK where we have over 100 different products on contract to supply the UK NHS.”